Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 3, 2003. The report primarily details corporate actions regarding share re-purchases and updates on directors' interests in company shares held through employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to share transactions:
- Share Re-purchase: 3,280,000 Ordinary 25 pence shares purchased for cancellation on February 28, 2003.
- Re-purchase Price: 1,085.2 pence per share.
- US Retirement Plan ADRs: Holdings decreased from 18,463,757 to 18,461,602 at an average price of $34.76.
- Employee Benefit Trust Sale: 2,220 ordinary shares sold on February 25, 2003, at £11.15 per share.
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 3,280,000 shares. Additionally, there were minor adjustments in the number of shares held by the GlaxoSmithKline US Retirement Savings Plan and the SmithKline Beecham Employee Benefit Trust due to fund movements and transfers to plan participants.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report confirming the execution of share buyback authority granted at the Annual General Meeting on May 20, 2002.
Key Facts for Investor Verification
- Verify the total number of shares repurchased under the May 2002 authorization to date.
- Confirm the impact of the 3,280,000 share cancellation on the company's total share count and earnings per share.
- Review the full details of the SmithKline Beecham 1991 Share Option Plan to understand the scope of director interests.
- Note that this filing does not contain quarterly or annual financial performance data.